Objective To report the effectiveness of physiotherapist-led interventions in improving pain and function in young and middle-aged adults with hip-related pain.
Design Systematic review and meta-analysis.
Data sources A comprehensive, reproducible search strategy was performed on five databases in May 2019. Reference lists and grey literature were also searched.
Eligibility criteria for selecting studies Population: people aged ≥18 years with hip-related pain (with or without a diagnosis of femoroacetabular impingement syndrome). Intervention(s): physiotherapist-led interventions for hip pain. Comparators: sham treatment, no treatment or other treatment (eg, hip arthroscopic surgery). Outcomes: primary outcomes included patient-reported hip pain and function. Secondary outcomes included physical function measures.
Results 1722 papers were identified. After exclusion criteria were applied, 14 studies were included for analysis. They had varied risk of bias. There were no full-scale placebo-controlled randomised controlled trials (RCTs) of physiotherapist-led treatment. Pooled effects ranged from moderate effects (0.67 (95% CI 0.07 to 1.26)) favouring physiotherapist-led intervention over no treatment post-arthroscopy, to weak effects (−0.32 (95% CI 0.57 to 0.07)) favouring hip arthroscopy over physiotherapist-led treatment.
Conclusion Physiotherapist-led interventions might improve pain and function in young and middle-aged adults with hip-related pain, however full-scale high-quality RCT studies are required.
PROSPERO registration number CRD42018089088.
This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.
Statistics from Altmetric.com
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Musculoskeletal conditions, such as hip-related pain, are leading causes of pain and disability in the community, and the second largest global contributor to years lived with disability.1 Hip and groin injuries are common in active individuals, for example, accounting for up to 18% of professional male football injuries.2–4 The true prevalence of non-arthritic hip pain in the general population is unknown, however the burden of hip pain is high, with younger adults with hip-related pain reporting poor patient-reported outcome scores for pain, physical activity and quality of life5–8 at a time of life where work and family commitments are large.
Hip-related pain may be classified into three categories, including femoroacetabular impingement (FAI) syndrome, acetabular dysplasia and other pathology without morphological variants (labral, chondral and ligamentum teres pathology).9 Of these, FAI syndrome is the most commonly diagnosed clinical condition10 and is evident in 49% of people with hip pain.11 Patients with FAI syndrome present with pain, a morphological variant in hip shape on radiographs, with or without intra-articular imaging findings such as labral and/or chondral pathology,12 and reduced activity and quality of life.13 14
Non-surgical treatment approaches should be the first-line options for musculoskeletal pain conditions (evident from clinical guidelines for osteoarthritis (OA)15 16 and low back pain,17 due to the far greater costs and risks associated with surgery. Establishing the efficacy of non-surgical treatments for hip pain is critical. Physiotherapist-led interventions have the potential to reduce the burden of hip pain, with current evidence guiding physiotherapist-led treatments to target characteristic modifiable physical impairments18 (strength, range of motion, functional task performance, neuromuscular/motor/movement control). At present, the level of evidence supporting the efficacy of physiotherapist-led interventions for hip pain and FAI syndrome is unclear.
This systematic review aimed to identify the effectiveness of physiotherapist-led interventions in improving pain and function in young and middle-aged adults who experience hip pain, when compared with sham treatment, no treatment and other treatment. This included non-operative and postoperative patient groups. This review specifically used the participants, interventions, comparators, outcomes (PICO) format.
This systematic review was conducted according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines. Literature search criteria and methods were proposed and agreed on by two authors (JK, SC), and were established a priori to minimise selection bias.
Eligibility criteria for selecting studies
Studies were eligible for inclusion if they were reported in English; reported level IV evidence or above; contained human subjects with hip pain; had at least 10 participants in the overall study sample (5 per group in studies with more than one group) and examined the effectiveness of physiotherapist-led interventions. All quantitative study designs were considered, including randomised controlled trials (RCTs), prospective or retrospective approaches.19 Studies were excluded if: hip pain was due to hip OA, dysplasia or congenital disorder; greater trochanteric pain syndrome and other conditions that are not related to the hip joint; the study evaluated other therapies that were not physiotherapist-led interventions; the study included populations of children or older adults (aged >50 years) or the study was a published abstract, non-peer-reviewed or was written in a language other than English.
People aged 18–50 years with hip pain (based on the mean or median age of the study sample), including studies that included a diagnosis of FAI syndrome.
Studies reporting physiotherapist-led interventions for hip pain and/or function were included.
Studies using sham treatment, no treatment or other treatment (eg, hip arthroscopy surgery) as the comparator/control treatment were included.
Primary outcomes included patient-reported hip pain and function. Secondary outcomes included: hip joint range of motion, hip muscle strength, functional task performance, electromyography (EMG) and motor control, balance and proprioception, biomechanics and gait analysis and other patient-reported outcome measures.
A comprehensive, reproducible search strategy was performed on the following databases from earliest available to 6 November 2017 and was then repeated on 20 May 2019: Medline, CINAHL, Cochrane library, EMBASE and PEDro. Reference lists of included studies were also manually searched for relevant papers. Grey literature, including the Clinical Trials database and the Australia and New Zealand Clinical Trials Registry were searched to identify potential studies that may have been published. Where data were insufficient, authors were contacted and asked to provide missing data. The search terms used PICO format and full search strategy of each database is contained in online supplementary appendix 1. The search strategy was conducted by two reviewers (JK, SC) and used the PICO format, and included:
P=human adults (18–50 years) with hip pain.
C=sham treatment, no treatment, other treatment (eg, surgery).
O=pain, function, other patient-reported outcome measures. Function may include hip joint range of motion, hip muscle strength, measures of functional task performance, EMG, gait analysis.
We also used Web of Science to track the forward and backward citations and reference lists of included studies. The strategy was adapted as appropriate for each database. The full search strategy used is contained in online supplementary appendix 1.
Title, abstract and full-text screening was conducted by two independent reviewers (JK, HH) using Covidence (Veritas Health Innovation, Australia) software. Any disagreements were resolved by a third independent reviewer (KC).
Risk of bias assessment
The Cochrane Collaboration Risk of Bias tool for Clinical Trials was used to appraise risk of bias. Included studies were rated by two independent reviewers (MB, MJS). Any disagreements between reviewers were discussed in a consensus meeting and an independent arbitrator (JK) was employed when consensus could not be met. Agreement between raters was determined using Cohen’s Kappa (κ). If risk of bias was high in >three out of five categories, overall study risk was rated as high, if risk was high in three out of five categories, study risk was moderate and if risk was high in <three out of five categories, overall study risk was rated as low.20 All studies were included in subsequent analyses, and sensitivity analyses were performed as appropriate.
Data extraction, synthesis and analyses
All potential references were imported into Endnote X7 (Thomson Reuters, Carlsbad, California, USA) and duplicates removed. Data were extracted by two independent reviewers (JK, ABM). Any discrepancies in data extraction were resolved by an independent arbitrator (KC).
Findings were summarised and population characteristics (age, gender, type and description of hip OA, duration of symptoms), and details of outcome measures, length of follow-up and type intervention undertaken were collated. We have reported main findings only for studies where the physiotherapist-led intervention was compared with a comparator/control intervention (RCT design) in order to ensure only higher quality evidence was included.
For studies of RCT design, follow-up scores were compared with the published Patient Acceptable Symptom State (PASS) scores for that outcome (if known) and change scores were compared with the published minimal important change (MIC) score for that outcome (if known). The proportion of people who achieve a PASS from follow-up scores was estimated using previously published methods, incorporating means, SD, sample size and z-scores.21 Previously published relevant PASS scores include 88 points (Hip Osteoarthritis and disability Outcome Score (HOOS)-pain)22 and 83 points (HOOS-quality of life (QOL))22 1-year posthip arthroplasty; 58 points (International Hip Outcome Tool (IHOT)-33)23 1–5 years posthip arthroscopy and 98 points (Hip Outcome Score (HOS)-activity of daily living (ADL))24 and 94 points (HOS-Sport)24 1-year posthip arthroscopy. Previously published MIC scores include 9 points (HOOS-pain),25 11 points (HOOS-QOL),25 10 points (IHOT-33)25 1–2 years posthip arthroscopy; 15 points (HOS-ADL)24 1-year posthip arthroscopy and 28 points (HOS-Sport) 6 months posthip arthroscopy.24
Data analyses were conducted by two investigators (AIS and JK). The ‘meta’ package (V.4.9–5), from the R statistical software package (V.3.5.1) was used to calculate relevant effect sizes, produce forest plots and pool data in a meta-analysis where relevant (https://www.r-project.org/). Standardised mean differences (SMD) were calculated for the studies of RCT design, to determine the magnitude of the effect of any interventions within groups or between groups. Where data were deemed statistically and clinically homogenous, meta-analyses were undertaken using a random effects model. In order to undertake SMD calculations in studies where non-normally distributed data were presented, the IQR was calculated.26 For analysis of outcomes that reported within group (pre-intervention to post-intervention), the standardised paired difference (SPD) was calculated from the sample size, mean and SD of the difference from pre-intervention to post-intervention time points. An additional requirement for SPD calculation was to account for the within-person correlation (r) between the two time points. If between-limb correlation was not reported, a conservative estimate of r=0.5 was used.27 Standardised mean/paired difference magnitude was interpreted as: ≥0.8 large effect; 0.5–0.79 moderate effect and 0.2–0.49 weak effect.28 Where SMDs could not be calculated, study conclusions were presented in tables, and best evidence synthesis was performed. For the best evidence synthesis, evidence was categorised as ‘strong’ if there were multiple high-quality clinical trials or cohort studies; ‘moderate’ if there was either one high-quality clinical trial or cohort study and more than two high-quality case-control studies or pilot clinical trials, or more than three high-quality case-control studies; ‘limited’ if there were either one or two case-control studies or pilot clinical trials, or multiple cross-sectional studies and ‘insufficient’ if there was not more than one cross-sectional study.20 All data used in calculations of SMDs and SPDs have been shared publicly at Figshare (https://figshare.com/s/d18bcb066f1de48861cf).
The search yielded 1722 titles and abstracts for screening. Sixty-five full texts were screened and 51 were excluded. There were 14 papers in the final analyses. An overview of the study identification process is provided in figure 1. Characteristics of the included studies are presented in table 1. The number of studies excluded along with reasons is provided in online supplementary appendix 2.
Risk of bias
Online supplementary appendix 3 contains the results of risk of bias assessment using the Cochrane Risk of Bias Tool. Agreement between raters occurred on 54 out of 70 items, where κ=0.65, which represents moderate agreement.29 Following discussion, consensus was obtained for all items. Overall results for the risk of bias assessment are mentioned in table 1. Three studies had a high risk of bias,30–32 seven studies had a moderate risk of bias7 33–38 and four studies had a low risk of bias.8 39–41 In the included studies, the overall risk of performance bias (blinding of participants and personnel) and detection bias (blinding of outcome assessors) was high (high in ≥nine studies); the risk of attrition bias (incomplete outcome data) and the risk of selection bias (random sequence generation and allocation concealment) was moderate (high in six to eight studies) and the risk of reporting bias (selective reporting of outcomes) was low (high in <six studies).
The 14 included studies contained 542 patients (283 men, 259 women) with sample sizes of the physiotherapist-led intervention groups ranging from 8 patients38 to 177 patients.7 Ten studies were of RCT design. Mean participant age ranged from 27 to 38 years, while the mean body mass index (BMI) ranged from 24.1 to 27.5 kg/m2. Ten studies included participants based on a diagnosis of FAI syndrome,8 10 30 31 33–35 37 38 40 41 with the remaining four studies including subjects based on a diagnosis of hip pain.30 32 36 39 Methods used for diagnostic inclusion criteria comprised surgical findings,28 clinical examination results8 10 14 30–32 35–41 and radiological findings.31 35 37 38 40 41 Two studies did not specify how FAI syndrome was diagnosed for inclusion33 34 (table 1). One study provided information about level of sports/physical activity,41 and no study provided detail about the duration of symptoms.
All included studies used a patient-reported outcome measure (PROM) as the primary outcome measure, but there was large heterogeneity in the PROMs used. The PROMs used included: the IHOT-33, the Copenhagen Hip and Groin Outcome Score (HAGOS), HOOS, the Oxford Hip Score (OHS), the Non-Arthritic Hip Score (NAHS), HOS, the Harris Hip Score (HHS), a pain Visual Analogue Scale (VAS), a Numeric Pain Rating Scale (NPRS), the Hip Sports Activity Scale (HSAS), a Global Rating of Change (GROC) score, the Hospital Anxiety and Depression Scale (HADS), the University of California, Los Angeles (UCLA) activity score, the European Quality of Life-5 Dimensions (EQ-5D) and the 36-item Short Form survey (SF-36) score.
Secondary outcomes measured were mostly measures of physical function, and included: hip muscle strength, trunk muscle strength, standardised hopping tests, measures of performance on a double-leg and single-leg squat, hip range of motion tests, the timed stair climb test and the Y-balance test. The methods used to measure these impairment-based outcomes varied widely between studies. Primary follow-up time points also varied and ranged from 3 weeks30 to 2 years.8 Most studies undertook a 3-month primary follow-up period (table 1).
Physiotherapist-led interventions performed
Seven studies included participants who had not undergone hip surgery,31 32 35 37–40 while three studies examined physiotherapist-led interventions posthip arthroscopy surgery,33 34 36 one study included both postsurgical and non-surgical participants30 and three studies compared physiotherapist-led interventions to hip arthroscopic surgery.7 8 41 The duration of physiotherapist-led interventions ranged from 3 weeks30 to 5 months.34 41
There was a large variety in the types of physiotherapist-led interventions performed. Nine studies included a strengthening programme,7 10 30 34–37 39–41 four studies included stretching/ROM exercises,7 8 10 31 five included ‘core stability’,7 30 38 39 41 eight studies included manual therapy,8 30 33 34 36–38 40 two studies included cardiovascular and return to sport retraining,33 40 two studies included functional retraining39 40 and six studies included neuromotor control exercises7 8 30 36 38 39 (table 1). Five studies did not report the interventions in sufficient detail to allow replication of the interventions.30–32 37 41
There was large heterogeneity in the control/comparator interventions used in the 10 RCTs. Control/comparator interventions used included (i) sham treatments, such as exclusion of pre-operative exercise advice,34 a standardised minimal intervention,40 education only,36 usual care (including medication and continuation of previous exercises)37 and a home-based unsupervised exercise programme38; (ii) no-treatment group33 or waiting-list control group39 and (iii) hip arthroscopy surgery7 8 41 (table 1).
Between-group differences were generated for physiotherapist-led interventions compared with the comparator intervention in four studies in patients who had not undergone surgery37–40; in three studies posthip arthroscopy33 34 36 and compared with hip arthroscopic surgery7 8 41 in three studies (table 2).
Between-group comparisons of physiotherapist-led interventions compared with sham/no treatment in non-surgical patients
The level of evidence was limited, with two high-quality39 40 and two moderate-quality37 38 pilot RCTs included. In patients with hip pain (non-surgical), physiotherapist-led interventions of 3 months duration that included targeted strengthening programmes showed moderate pooled effects for function (SMD (95% CI): 0.66 (0.09 to 1.23)) favouring the physiotherapist-led intervention group37 40 (figure 2). For physiotherapist-led interventions of shorter duration (6–8 weeks), effects showed no significant differences between groups (figure 3). One study achieved a follow-up score greater than the PASS score, and change score greater than the MIC for the primary outcome.40
Between-group comparisons of physiotherapist-led interventions compared with sham/no treatment in post-hip arthroscopy patients
The level of evidence was limited, with two moderate-quality pilot RCTs included.33 36 Data could not be pooled due to heterogeneity in outcomes assessed. Moderate positive effects for patient-reported function (0.67; 95% CI 0.07 to 1.26) were reported in the two RCTs, favouring the physiotherapist-led interventions (figure 4). Both studies achieved a follow-up score greater than the PASS score and change score greater than the MIC for the primary outcome. The proportion of participants undertaking physiotherapist-led interventions achieving a score greater than the PASS score ranged from 11%36 to 90%.33
Between-group comparisons of physiotherapist-led interventions compared with hip arthroscopic treatment
The level of evidence was strong, with two high-quality RCTs8 41 and one moderate-quality RCT7 included (figure 5). In studies comparing physiotherapist-led interventions with hip arthroscopic surgery, at 8–12 months, weak positive pooled effects (−0.32; 95% CI −0.57 to −0.07) favoured hip arthroscopy surgery. At 24 months, there was only one moderate-quality RCT and thus the level of evidence is limited. There was no significant difference between groups (−0.18; 95% CI −0.64 to 0.28). For the physiotherapist-led intervention groups, no studies achieved a follow-up score greater than the PASS score, and only one study had a change score greater than the MIC for the primary outcome.7 The proportion of participants undertaking physiotherapist-led interventions achieving a score greater than the PASS score ranged from 7%41 to 37%.7
Within-group change for patient-reported outcome measures for physiotherapist-led interventions in non-operative patient groups
Within-group effects for physiotherapist-led interventions on PROMS in patients with hip pain were able to be calculated for nine of the included studies7 8 30–32 37–40 (table 3). The level of evidence overall was moderate, with one high-quality RCT and several high-quality pilot RCTs included in the analyses. Positive SPDs ranged from moderate effects for patient-reported function (0.57; 95% CI 0.03 to 1.12)37 following a 3-month intervention, to large positive effects for function (3.85; 95% CI 2.91 to 4.78)31 following a 6-month intervention. Data were not able to be pooled due to heterogeneity between time points and the outcomes measured. The proportion of participants undertaking physiotherapist-led interventions achieving a score greater than the PASS score ranged from 25%38 39 to 86%.40
Within-group change for physical impairments for physiotherapist-led interventions in non-operative patient groups
Nine studies reported the effects of physiotherapist-led interventions on physical impairments on people with hip pain30 31 34 35 37–41 (table 3), with SPDs able to be calculated for seven of the nine studies. The level of evidence was limited, with no high-quality, full-scale RCTs included in any of the analyses relating to physical impairments. The impairment measures included hip range of motion,30 31 38 40 hip muscle strength,35 38–40 depth of squat,38 balance,30 trunk endurance,40 control during single leg squat39 and hopping performance.38 40 Data were not able to be pooled for within-group change in physical impairment measures, due to heterogeneity between time points and the methods by which outcomes were measured.
For hip flexion range of motion, SPDs varied, and ranged from large negative changes (2.07, 95% CI –2.64 to −1.50) following a 6-month intervention consisting of rest, stretching and activity modification31 to large positive change (1.08, 95% CI 0.49 to 1.68) following a 3-month intervention comprising strengthening exercise, manual therapy and education.40
Hip muscle strength was recorded in four studies,35 38–40 and SPDs ranged from weak, non-significant effects (0.09,–0.35 to 0.53) for an 10 week intervention comprising progressive strengthening exercises,35 to large positive SMDs (1.19, 0.57 to 1.81) for a 12 week intervention comprising targeted strengthening and functional retraining exercises.40
There were varied within-group changes in functional task performance. Positive SPDs ranged from moderate improvements in the timed stair climb test (0.57, 95% CI 0.10 to 1.05),35 single-leg hop test (0.65, 95% CI 0.12 to 1.17)40 and Y-balance test (0.63, 95% CI 0.29 to 0.97)30 with movement retraining and functional exercise programmes, to large improvements for trunk endurance (0.95, 95% CI 0.38 to 1.53) following a 3-month targeted trunk-strengthening programme.40
Our systematic review evaluated the effectiveness of physiotherapist-led interventions to improve pain and function in young and middle-aged adults experiencing hip-related pain, including those with FAI syndrome. The 14 studies included 7 pilot and 3 full-scale RCTs, and demonstrated considerable variability in the risk of bias, the outcomes reported and the interventions performed, which limited opportunities for meta-analysis. Included studies had poor transparency in reporting of interventions, inconsistency in PROMs and methods used to measure physical impairments.
Our findings suggest that in people with hip pain, physiotherapist-led interventions may improve function and strength, however the effects on pain and QOL were unclear. There was limited evidence that interventions with targeted strengthening exercise programmes that were at least 3 months duration might have the best effect. Hip arthroscopy surgery had a small positive benefit compared with a physiotherapist-led intervention at 8–12 months. At 24 months, the level of evidence was limited indicating no difference between the hip arthroscopy surgery and physiotherapist-led interventions. Very few of the physiotherapist-led interventions in this review achieved follow-up and change scores that surpassed previously published PASS and MIC scores.
Physiotherapist-led interventions for those who had and had not undergone hip arthroscopy surgery for hip pain primarily comprised exercise therapy, where the types of exercise described included strength training, movement pattern retraining, range of motion exercises and stretching. However, specific details of the programmes were rarely well described. The moderate effect observed for these interventions were hampered by small sample sizes and require full-scale RCTs to confirm findings. Extending the outcome measurement beyond the 3-month mark would determine whether improvements seen would be maintained in the medium-term to long-term. A recent consensus meeting reported considerable discord in the type, duration, intensity and modality of posthip arthroscopy rehabilitation provided by physiotherapists.42 The consensus group suggested that full-scale RCTs are required in order to gain clarification on the composition of optimal postarthroscopic rehabilitation programmes.42
Physiotherapist-led intervention was inferior to hip arthroscopy surgery with small between-groups differences at 12-month follow-up.7 8 41 Not surprisingly, despite the small difference favouring surgery, physiotherapy was far more cost-effective (£155 for physiotherapist-led treatment compared with £2372 for hip arthroscopy).7 Arthroscopic surgery could be recommended as a second-line treatment for patients who have not responded adequately to a physiotherapist-led treatment programme.42 However, the mean effects beyond that of physiotherapy were weak and may not be clinically meaningful. The within-group improvements for the physiotherapist-led interventions in these studies were modest, with only one study achieving the PASS, and they may not represent optimal treatment.18 Further studies might shed more light on the relative effectiveness of surgery and physiotherapy particularly in the medium-term and long-term.43
Multimodal, physiotherapist-led interventions,7 8 30 33 34 36–38 40 including exercise therapy combined with manual therapy, medication, activity modification, advice and education, were most commonly studied. Manual therapy is effective when combined with exercise for hip OA,44 45 but there is debate whether contemporary physiotherapist-led interventions for musculoskeletal pain should include multimodal treatment additions such as manual therapy.42 Further studies are required to confirm whether additional treatment elements, such as manual therapy, impart a greater benefit than exercise-therapy alone for young and middle-aged adults with hip pain.
Physiotherapist-led interventions on physical impairments had variable effects. For hip range of motion, the largest positive effects pre-physiotherapist-led to post-physiotherapist-led treatment were seen following a 3-month intervention strengthening exercise, manual therapy and education.40 The greatest hip muscle strength gain was seen with a strengthening exercise programme of 3 months duration,40 and largest in hip adductor muscles. Greater hip adductor strength following hip arthroscopy is associated with better hip-related QOL,46 suggesting that it may be an important target. However, this was a pilot study, and the most effective type, dose and progression of exercise is unknown. The American College of Sports Medicine47 guidelines for exercise prescription contain information about the dosage, volume and progression of exercises that may be useful for clinicians and researchers when developing strength programmes for patients with hip pain. In studies measuring changes in functional task performance, had positive effects30 35 40 with movement retraining and functional exercise programmes. These programmes may improve patient self-efficacy as well as increase the capacity for load, thus enabling participation in more challenging activity. Larger, future studies including evaluating the potential of effect mediators and moderators may provide insight into the most effective physiotherapist-led interventions to improve physical impairments.
Returning to pre-injury sport and activity is important to young and middle-aged people with hip pain, and often the reason they seek surgical and/or non-surgical treatment.10 48 However, only two studies in this review had a specific return to sport/return to physical activity component within the physiotherapist-led intervention.33 40 Only 17% of people returned to optimal performance and full sports participation at 33±16 months following hip arthroscopy.48 Given the importance of returning to sport in this active patient group and the disappointing rates of returning to optimal performance reported,48 future studies should incorporate key functional and sporting components.49 These could include: valid and consistent definitions of what comprises a successful return to sport and return to activity50; fully powered RCTs that include a specific, targeted return to sport programme throughout the duration of the intervention50 and inclusion of return to sport outcomes as a continuum.40 Until physiotherapist-led interventions include high-quality return to sport elements, outcomes are unlikely to improve beyond those reported by Ishoi et al.48
Transparency and reproducibility are critical when reporting the efficacy of clinical interventions. Guidelines such as the Consensus on Exercise Reporting Template51 and Template for Intervention Description and Replication checklist52 should be used in all trials reporting interventions to ensure adequate transparency and reproducibility. In addition, describing targeted strengthening interventions should use detailed procedures such as those described by Toigo and Boutellier.53 The documentation of adherence to exercise programmes is also critical. Such guidelines allow researchers to evaluate interventions and clinicians to reproduce efficacious interventions in clinical practice. Very few studies used these guidelines to report interventions in the current review. As such, it was not possible to pool findings to complete a meta-analysis, limiting the scope of the review. We recommend that future studies report physiotherapist-led interventions using guidelines such as those described above to maximise transparency and utility of study findings by researchers and clinicians alike.
This review contains several limitations that should be acknowledged. First, the methodological quality of the studies was variable, with only 4/14 (29%) studies considered to have a low risk of bias. In the studies with a higher risk of bias, inflated effect sizes are possible, raising questions about the strength of the findings of these studies. Second, most of the included RCTs were pilot studies and as such were underpowered to detect statistically significant differences between groups. In addition, as there were no fully powered studies comparing physiotherapist-led interventions with sham interventions, adequately powered studies that undertake a head-to-head comparison of physiotherapist-led interventions are required to determine the optimal management strategies for hip pain in young and middle-aged adults. Furthermore, the terminology used to describe hip disorders is not clear, and the populations that were included in this review may be heterogenous. The recent Zurich consensus statement on hip-related pain has provided some guidance in classifying hip disorders as FAI syndrome, acetabular dysplasia and ‘other’.9 At present, there are not enough studies published to be able to analyse data separately for each of these three classifications. However, as the field evolves, this may be an approach that is appropriate for future reviews. As with all reviews of intervention studies, publication bias may have existed where studies with negative findings were not published. We also excluded studies not written in English, which may have led to inclusion bias. Finally, the PROMs and physical impairment-based outcome measures used in the studies were inconsistent, which limited the pooling of data. A recent consensus54 determined that the HAGOS and IHOT were the most appropriate PROM for use in young and middle-aged people with hip pain, and future studies using these measures may make stratification and pooling of data based on these measures in future reviews possible. Furthermore, it is not yet clear what is considered an acceptable level of improvement in a patient’s condition. We compared the findings of our review to previously published PASS and MIC scores, to provide some context to clinical relevance of the effects reported. We acknowledge that the previously published PASS and MIC scores were determined in studies of posthip arthroscopy and posthip arthroplasty patients. It is not known what constitutes a PASS and MIC in non-surgical cohorts of people with hip-related pain. The inclusion of PASS questions at specific time points in future studies may help determine whether patients are gaining acceptable improvement when undergoing physiotherapist-led interventions.
There were no full-scale RCTs comparing physiotherapist-led interventions with other non-surgical treatments or sham treatments. The risk of bias in included studies, as well as limitations in included study methodology should be considered in the interpretation of the results of this systematic review. Physiotherapist-led interventions may improve pain and function in young and middle-aged adults experiencing hip pain, including those with FAI syndrome. There was limited evidence of larger effects for interventions that included targeted strengthening exercise programmes and were of 3 months duration. Hip arthroscopy surgery had a weak positive effect compared with a physiotherapist-led intervention at 8–12 months. Future full-scale RCTs undertaking a head-to-head comparison of physiotherapist-led interventions for hip pain are required.
What is already known?
Hip-related pain is common in young, active adults.
Non-surgical treatments such as physiotherapist-led treatments should be first-line treatment for musculoskeletal conditions including hip-related pain, but effectiveness of these treatments is unclear.
What are the new findings?
There is a paucity of literature in this field.
Physiotherapist-led interventions improve function and strength.
Effects of physiotherapist-led interventions on pain and quality of life are uncertain.
Targeted strengthening exercise programmes and at least 3-month duration might have the best effect.
Hip arthroscopy surgery had a small positive benefit compared with a physiotherapist-led intervention at 8–12 months.
At 24 months, there was limited evidence suggesting no difference between groups.
Twitter @JoanneLKemp, @AndreaBMosler, @MarkScholes85, @ASemciw
Correction notice This article has been corrected since it published Online First. An ORCID ID has been added for author Steven Chang.
Contributors JK, AMB, KMC developed the research question and concept. JK and SC performed the search. JK, HH, MB, MJS performed risk of bias assessment. JK and AMB performed data extraction. JK and AIS performed data analyses. All authors contributed to drafting of manuscript.
Funding JK is supported by an NHMRC (Australia) ECF 1119971.
Competing interests None declared.
Patient consent for publication Not required.
Ethics approval Institutional ethical approval was not required as no data were collected on humans or animals in this review.
Provenance and peer review Not commissioned; externally peer reviewed.
Data availability statement Data extracted are shared at Figshare (https://figshare.com/s/d18bcb066f1de48861cf).